Literature DB >> 12917965

Treatments for gestational diabetes and impaired glucose tolerance in pregnancy.

D J Tuffnell1, J West, S A Walkinshaw.   

Abstract

BACKGROUND: Gestational diabetes and impaired glucose tolerance (IGT) in pregnancy affects between 3 and 6% of all pregnancies and both have been associated with pregnancy complications. A lack of conclusive evidence has led clinicians to equate the risk of adverse perinatal outcome with pre-existing diabetes. Consequently, women are often intensively managed with increased obstetric monitoring, dietary regulation, and in some cases insulin therapy. However, there has been no sound evidence base to support intensive treatment. The key issue for clinicians and consumers is whether treatment of gestational diabetes and IGT will improve perinatal outcome.
OBJECTIVES: The objective of this review was to compare alternative policies of care for women with gestational diabetes and IGT in pregnancy. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group trials register (12 September 2002) and the bibliographies of relevant papers. The Cochrane Central Register of Controlled Trials was also searched (The Cochrane Library, Issue 3, 2002). SELECTION CRITERIA: Randomised controlled trials comparing alternative management strategies for women with gestational diabetes and IGT in pregnancy. DATA COLLECTION AND ANALYSIS: Quality was assessed according to the criteria defined by the Cochrane Reviewers' Handbook. Data were extracted and checked independently by two reviewers. Any disagreements were resolved through discussion with the third reviewer. MAIN
RESULTS: Three studies with a total of 223 women were included. All three included studies involved women with IGT. No trials reporting treatments for gestational diabetes met the criteria. There are insufficient data for any reliable conclusions about the effect of treatments for IGT on perinatal outcome. The difference in abdominal operative delivery rates is not statistically significant (relative risk (RR) 0.86, 95% confidence interval 0.51 to 1.45) and the effect on special care baby unit admission is also not significant (RR 0.49, 95% confidence interval (CI) 0.19 to 1.24). Reduction in birthweight greater than 90th centile (RR 0.55, 95% CI 0.19 to 1.61) was not found to be significant. This review suggests that an interventionist policy of treatment may be associated with a reduced risk of neonatal hypoglycaemia (RR 0.25, 95% CI 0.07 to 0.86). No other statistically significant differences were detected. A number of outcomes are only reported by one study resulting in a small sample and wide confidence intervals. REVIEWER'S
CONCLUSIONS: There are insufficient data for any reliable conclusions about the effects of treatments for impaired glucose tolerance on perinatal outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917965     DOI: 10.1002/14651858.CD003395

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  14 in total

1.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

Review 2.  Reducing stillbirths: screening and monitoring during pregnancy and labour.

Authors:  Rachel A Haws; Mohammad Yawar Yakoob; Tanya Soomro; Esme V Menezes; Gary L Darmstadt; Zulfiqar A Bhutta
Journal:  BMC Pregnancy Childbirth       Date:  2009-05-07       Impact factor: 3.007

Review 3.  Controversies around gestational diabetes. Practical information for family doctors.

Authors:  Len Kelly; Laura Evans; David Messenger
Journal:  Can Fam Physician       Date:  2005-05       Impact factor: 3.275

4.  Gestational diabetes mellitus: why screen and how to diagnose.

Authors:  T Karagiannis; E Bekiari; K Manolopoulos; K Paletas; A Tsapas
Journal:  Hippokratia       Date:  2010-07       Impact factor: 0.471

Review 5.  Maternal metabolism and obesity: modifiable determinants of pregnancy outcome.

Authors:  Scott M Nelson; Phillippa Matthews; Lucilla Poston
Journal:  Hum Reprod Update       Date:  2009-12-04       Impact factor: 15.610

6.  Maternal serum adiponectin multimers in gestational diabetes.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Edi Vaisbuch; Offer Erez; Pooja Mittal; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Percy Pacora; Lami Yeo; Francesca Gotsch; Zhong Dong; Bo Hyun Yoon; Sonia S Hassan; Juan Pedro Kusanovic
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

Review 7.  Gestational diabetes and nutritional recommendations.

Authors:  Erica P Gunderson
Journal:  Curr Diab Rep       Date:  2004-10       Impact factor: 4.810

Review 8.  Treatments for gestational diabetes.

Authors:  Nisreen Alwan; Derek J Tuffnell; Jane West
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

Review 9.  Fetoplacental vascular endothelial dysfunction as an early phenomenon in the programming of human adult diseases in subjects born from gestational diabetes mellitus or obesity in pregnancy.

Authors:  Andrea Leiva; Fabián Pardo; Marco A Ramírez; Marcelo Farías; Paola Casanello; Luis Sobrevia
Journal:  Exp Diabetes Res       Date:  2011-11-24

Review 10.  Effect of screening and management of diabetes during pregnancy on stillbirths.

Authors:  Madiha Syed; Hasan Javed; Mohammad Yawar Yakoob; Zulfiqar A Bhutta
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.